期刊
CURRENT OPINION IN GENETICS & DEVELOPMENT
卷 33, 期 -, 页码 32-40出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.gde.2015.07.002
关键词
-
资金
- Generalitat de Catalunya [SGR0489-2009, SGR317-2014]
- ICREA-Academia Program
- Marato de TV3 [464/C/2012]
- Spanish Ministry of Science and Innovation [CB06/07/0023, SAF2012-31881]
- European Commission (EUROFANCOLEN) [HEALTH-F5-2012-305421]
- European Regional Development FEDER Funds
Fanconi anemia (FA) is characterized by bone marrow failure, malformations, and chromosome fragility. We review the recent discovery of FA genes and efforts to develop genetic therapies for FA in the last five years. Because current data exclude FANCM as an FA gene, 15 genes remain bona fide FA genes and three (FANCO, FANCR and FANCS) cause an FA like syndrome. Monoallelic mutations in 6 FA associated genes (FANCD1, FANCJ, FANCM, FANCN, FANCO and FANCS) predispose to breast and ovarian cancer. The products of all these genes are involved in the repair of stalled DNA replication forks by unhooking DNA interstrand cross-links and promoting homologous recombination. The genetic characterization of patients with FA is essential for developing therapies, including hematopoietic stem cell transplantation from a savior sibling donor after embryo selection, gene therapy, or genome editing using genetic recombination or engineered nucleases. Newly acquired knowledge about FA promises to provide therapeutic strategies in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据